A First-in-patient Phase I/II Clinical Study to Investigate the Safety, Tolerability and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Subjects With Severe Complications of Sickle Cell Disease is a PHASE1 clinical asset sponsored by Novartis Pharmaceuticals in Sickle Cell Disease. SEO and diligence focus: OTQ923, OTQ923, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.